LEUVEN, BELGIUM – March 4, 2025 – 07:00PM – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the signing of a third amendment to its convertible bond subscription agreement with Atlas Special Opportunities, LLC. As part of this amendment, the agreement has been assigned to Atlas Special Opportunities II, LLC. This amendment extends the issuance period under adjusted conditions and clarifies the maturity terms of all outstanding and future bonds.
Key Amendments to the Financing Terms
- Program extension:
- Oxurion may continue issuing convertible bonds under lighter conditions until December 2025.
- The overall financing program remains in place until March 2, 2026.
- Bond maturity adjustment: The maturity date of all bonds, whether already issued or to be issued, is now set at 60 months from their respective issuance dates. This ensures a standardized maturity structure across all outstanding bonds.
- Market capitalization condition: A minimum EUR 500,000 over a rolling 30-day period is required for bond issuance. If the market capitalization temporarily drops to EUR 250,000, a partial drawdown of EUR 150,000 remains possible under specific conditions.
- Liquidity condition: A total trading value of at least EUR 1.2 million over 22 consecutive trading days is required, with a reduced threshold of EUR 600,000 for partial drawdowns.
- Monthly tranches: The base monthly issuance remains EUR 300,000, with potential increments of EUR 100,000, subject to subscriber approval. No cool down period is applicable.
Summary Table
| Aspect | Value |
| Minimum market capitalization | EUR 500,000 |
| Threshold for partial drawdown | EUR 250,000 |
| Total trading volume over 22 days | EUR 1.2 million |
| Threshold for partial drawdown | EUR 600,000 |
| Monthly bond issuance | EUR 300,000 |
| Possible increments | EUR 100,000 |
| Issuance period under lighter conditions | Until December 2025 |
| Program extension | Until March 2, 2026 |
| Maturity of all bonds | 60 months from issuance |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biotechnology company specialising in the development of
next-generation standard ophthalmic therapies for the treatment of retinal diseases. Oxurion is
headquartered in Leuven. Further information is available at www.oxurion.com
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based
on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company
therefore, cannot provide any assurance that such forward-looking statements will materialize and does not assume any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any
other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could
cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S.
Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
For further information please contact:
| OXURION NV: Pascal Ghoson, CEO pascal.ghoson@oxurion.com |